Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

There are a total of 93 products in Phase I-III development for PD treatment. The Parkinson’s disease (PD) therapeutic ...

None are truly reflective of human glaucoma. Although there are a plethora of candidate neuroprotective agents identified from experimental and animal settings, only a handful have been translated ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

Huntington’s Disease (HD) is a fatally inherited neurodegenerative, orphan disorder affecting 1 in 10,000 individuals with a higher prevalence in Caucasian race. HD is caused by an expanded glutamine ...

Crucially, neuronal damage was also significantly reduced in rats treated with Indip 120 min after transient middle cerebral artery occlusion, which suggests that this agent has neuroprotective ...

Despite significant advances in laboratory modeling, there is still no clinical evidence for an effective neuroprotective agent for the management of glaucoma. By contrast, there has been ...

The pipeline distribution highlights a strong emphasis on neuroprotective and disease-modifying agents, reflecting the ...

66% of these are prospective neuroprotective agents or DMTs. These investigational agents target the key mechanisms that have been implicated in the pathophysiology of PD, such as alpha-synuclein ...